HealthMore in Health→
FDA clears Gilead’s hepatitis D treatment after a four-year delay tied to manufacturing issues
Key Takeaways
- The FDA approved Gilead’s hepatitis D drug Hepcludex.
- The therapy had been rejected four years earlier over manufacturing and distribution issues.
- The decision highlights how operational readiness can determine whether a drug reaches market.
DE
DT Editorial Team··via endpoints.news
